Astarcioglu Ibrahim, Egeli Tufan, Unek Tarkan, Akarsu Mesut, Sagol Ozgul, Obuz Funda, Ozbilgin Mucahit, Aysal Agalar Anil, Ağalar Cihan
From the Department of General Surgery, Hepatopancreaticobiliary Surgery and Liver Transplantation Unit, Dokuz Eylul University Faculty of Medicine, Narlıdere, Izmir, Turkey.
Exp Clin Transplant. 2018 Aug;16(4):434-438.
Primary sclerosing cholangitis is a chronic inflammatory disease of the intrahepatic and extrahepatic bile ducts. More than half of the patients will face end-stage liver disease and require liver transplant. Here, we describe the long-term outcomes of liver transplant in patients with primary sclerosing cholangitis at our center.
For this retrospective, observational study, we investigated all patients who underwent liver transplant for primary sclerosing cholangitis between January 2005 and June 2013 at the Dokuz Eylul University Hospital. Patient data were obtained from hospital records. Our inclusion criteria were patients over 18 years old and diagnosed with primary sclerosing cholangitis.
Of 11 patients included the study, 6 (54.5%) were male and 5 (45.5%) were female. Mean age was 40.6 ± 11.0 years (range, 23-60 y). All patients had cirrhosis due to primary sclerosing cholangitis. With regard to Child-Turcot-Pugh classification, 2 patients (18.2%) were classified as having Child-Turcot-Pugh A cirrhosis, 7 patients (63.6%) were classified as having B cirrhosis, and 2 patients (18.2%) were classified as having C cirrhosis. Mean Modified End-Stage Liver Disease score was 17.5 ± 6.1 (range, 7-25). Cholangiocarcinoma was not detected in explant pathologic examinations. Primary sclerosing cholangitis recurrence developed in 2 patients (18.1%). Three patients (27.2%) died during the follow-up period.
Liver transplant is a good therapeutic option for primary sclerosing cholangitis with satisfactory long-term outcomes. Liver transplant should be reserved for patients with end-stage liver disease and other conditions that significantly impair quality of life.
原发性硬化性胆管炎是一种肝内和肝外胆管的慢性炎症性疾病。超过半数的患者将面临终末期肝病并需要肝移植。在此,我们描述了本中心原发性硬化性胆管炎患者肝移植的长期结局。
对于这项回顾性观察研究,我们调查了2005年1月至2013年6月在多库兹艾吕尔大学医院因原发性硬化性胆管炎接受肝移植的所有患者。患者数据来自医院记录。我们的纳入标准为年龄超过18岁且被诊断为原发性硬化性胆管炎的患者。
纳入研究的11例患者中,6例(54.5%)为男性,5例(45.5%)为女性。平均年龄为40.6±11.0岁(范围23 - 60岁)。所有患者均因原发性硬化性胆管炎导致肝硬化。关于Child-Turcot-Pugh分类,2例患者(18.2%)被分类为Child-Turcot-Pugh A级肝硬化,7例患者(63.6%)被分类为B级肝硬化,2例患者(18.2%)被分类为C级肝硬化。平均终末期肝病改良评分是17.5±6.1(范围7 - 25)。在移植肝病理检查中未检测到胆管癌。2例患者(18.1%)发生原发性硬化性胆管炎复发。3例患者(27.2%)在随访期间死亡。
肝移植是原发性硬化性胆管炎的一种良好治疗选择,长期结局令人满意。肝移植应保留给终末期肝病和其他严重损害生活质量的患者。